MVM Life Science Partners: A global venture capital firm investing in healthcare and pharmaceutical sectors.
35
Operating
MVM Partners is a global venture capital firm specializing in healthcare investments. With teams in Boston and London, the firm focuses on medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. MVM typically invests in Series B to Series E rounds, with a broad investment outlook spanning various stages of company growth.
The firm's portfolio includes notable companies such as Cara Therapeutics, GT Medical Technologies, and Vero Biotech. MVM partners with management teams to bring innovative products to market, drive growth, and make strategic acquisitions. With over $1 billion in assets under management and extensive experience in healthcare investing, MVM offers valuable expertise and support to its portfolio companies.
Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies19
Follow-on Investments
9
Current Portfolio Count16
Total Portfolio Exits3
Top Investment Stages
Series B6 (25.0%)
Series C6 (25.0%)
Series D6 (25.0%)
Series E4 (16.7%)
Series A2 (8.3%)
Stage Mix
Series B 25%Series C 25%Series D 25%Series E 17%Series A 8%
Concentration shown as share of disclosed investments by stage.